
“Revolutionizing Chronic Back Pain Treatment: Positive Results from Phase 1/2 Trial of CELZ-201 DDT Announced by Creative Medical Technology Holdings”
The Revolutionary Treatment for Chronic Back Pain A Breakthrough in Regenerative Medicine Phoenix, Jan. 30, 2025 (GLOBE NEWSWIRE) – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), has recently announced groundbreaking initial data from the first cohort of its Phase 1/2 clinical trial of CELZ-201-DDT. This innovative stem cell-based therapeutic is designed to target chronic back…